CRISPR Therapeutics Strengthens Its Leadership Team with the Appointment of Marc Becker as Chief Financial Officer
CRISPR Therapeutics , a biopharmaceutical company focused on developing transformative gene-based medicines for patients with serious diseases, today announced the appointment of Marc Becker as Chief Financial Officer to further support the Company’s efforts to develop game-changing drugs derived from its proprietary CRISPR-Cas9 gene-editing technology platform. Mr. Becker is a seasoned executive who brings more than 20 years of experience in commercial, operational and corporate finance and a deep understanding of the global biopharmaceutical industry.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160310005637/en/
Prior to joining CRISPR Therapeutics, Mr. Becker served as Chief Financial Officer and Senior Vice President of rEVO Biologics, a commercial stage company with research, clinical, and manufacturing operations. At rEVO, Mr. Becker led the finance team in anticipation of raising private and public capital, outlined the market opportunity for the Company and managed its governance and SEC Compliance through S-1 filing and IPO Road Show.
“Marc’s experience with biopharmaceutical companies in various stages of the lifecycle, expertise in identifying capital market opportunities and his ability to effectively establish core business operations will be invaluable to CRISPR Therapeutics at this time of growth for our company,” said Rodger Novak, M.D., Chief Executive Officer of CRISPR Therapeutics. “Marc’s extensive network and proven track record to establish internal controls will be vital as we continue to engage in key strategic ventures to support the discovery, development and commercialization of new breakthrough therapeutics.”
Prior to rEVO, Mr. Becker spent 10 years at Genzyme, most recently serving as Finance Director for the UK and Ireland before returning to the United States to become the Vice President of Finance for Genzyme’s $1.1 billion Renal and Endocrine business. Mr. Becker had global P&L responsibility with multiple product lines, large scale, and reimbursement complexity.
Mr. Becker started his career in auditing and commercial lending for financial services firms, KPMG and BankBoston. Mr. Becker holds a BS from the University of Massachusetts, an MBA from Babson College and was licensed as a CPA.
“I am excited to join the CRISPR Therapeutics leadership team as the Company’s growth accelerates with the introduction of strategic partnerships and ventures,” said Mr. Becker. “Our technology is truly revolutionary and I’m delighted to be part of the team that will enable the development of life-changing medicines.”
CRISPR Therapeutics is focused on the discovery and development of potential cures for serious diseases using its proprietary CRISPR-Cas9 gene editing technology. The Company’s multi-disciplinary team of world-class drug developers, clinicians and academics is working on its own proprietary product pipeline and also partnering with some of the world’s leading pharmaceutical and biotechnology companies to translate this technology into breakthrough human therapeutics. The foundational CRISPR-Cas9 patent estate for human therapeutic use was licensed from scientific founder Emmanuelle Charpentier, Ph.D. CRISPR Therapeutics recently entered into substantial strategic partnerships with Vertex Pharmaceuticals and Bayer .
CRISPR Therapeutics is headquartered in Basel, Switzerland with its R&D operations based in Cambridge, Massachusetts. For more information, please visit www.crisprtx.com .
W2O Group for CRISPR
Jennifer Paganelli, 347-658-8290
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
ERYTECH-PHARMA24.4.2018 22:32 | pressemeddelelse
ERYTECH Announces Filing of 2017 “Document de Référence” and 2017 Annual Report on Form 20-F
NV-RIMINI-STREET24.4.2018 18:02 | pressemeddelelse
Rimini Street Launches New Solutions that Further Extend the Life and Value of Enterprise Software as a Foundation for Innovation
NOVALIQ-GMBH24.4.2018 17:55 | pressemeddelelse
Novaliq to Present Scientific and Clinical Research During the 2018 Association for Research in Vision and Ophthalmology Meeting in Honolulu, HI
PA-PPG24.4.2018 15:09 | pressemeddelelse
PPG Reports Sustainability Progress, New 2025 Goals
BIOIBERICA24.4.2018 14:19 | pressemeddelelse
Bioiberica Approves Its Combined Drug for Osteoarthritis in Five More European Countries
TX-ASURAGEN24.4.2018 14:03 | pressemeddelelse
Asuragen to Present at World CB & CDx Europe Summit in London, UK
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum